Du är här

2014-05-28

Nestlé S.A.: Nestlé to acquire aesthetic dermatology assets for Nestlé Skin Health

Nestlé S.A. / Nestlé to acquire aesthetic dermatology assets for Nestlé Skin
Health. Processed and transmitted by NASDAQ OMX Corporate Solutions. The
issuer is solely responsible for the content of this announcement.
This press release is also available inFrench (pdf)andGerman (pdf)

.............

Vevey, 28 May 2014 -
On 11thFebruary 2014, Nestlé announced it would extend its activities to
include the field of specialised medical skin treatments through the creation
of Nestlé Skin Health S.A., a global leader focused on meeting the world's
increasing skin health needs with a broad range of innovative and
scientifically-proven products. The foundation for the company would be
Galderma, the 50/50 joint venture with L'Oréal, which would become
fully-owned by Nestlé.Bübchen
, our existing infant skincare business would be merged into the new entity.
The acquisition of Galderma is awaiting final regulatory clearance.

Today Nestlé is announcing it will reinforce Nestlé Skin Health with the
acquisition from the Canadian firm Valeant Pharmaceuticals International of
the full rights to commercialise several key aesthetic dermatology products
in the US and Canada for USD 1.4 billion in cash. The two markets together
represent more than half of the fast-growing medical aesthetics market around
the world. Galderma already commercialises the products included in this
transaction outside those markets.

Nestlé is acquiring the full rights to commercialise in the US and
CanadaRestylane,Perlane
andEmervel,
products used for corrective facial aesthetic treatments, andDysport
, an aesthetic dermatology treatment. It will also acquire the full rights
toSculptra
, a unique treatment for aesthetic and medical uses in the US, Canada and many
markets around the world.

"With this deal we have acquired key strategic assets to extend Nestlé's
activities in the field of specialised, medical skin treatments, providing
consumers with life-enhancing scientific products," said Nestlé Chairman
Peter Brabeck-Letmathe.

"This move will reinforce Galderma's leading position in the industry when it
becomes Nestlé Skin Health by allowing it to complete its geographic
footprint for its strong portfolio of brands and leading medical solutions
globally," said Nestlé Chief Executive Paul Bulcke.

The transaction is subject to regulatory approval and customary closing
conditions.

Contacts
Media: Robin Tickle Tel. +41 21 924 22 00
Investors: Tel. +41 21 924 35 09

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nestlé S.A. via Globenewswire

HUG#1789015

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.